Drug Trial Radar · NCT00536484
Fesoterodine Flexible Dose Study
Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
896
Actual
Start
Aug 2007
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 27, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.
Conditions
- Overactive Bladder
Interventions
FesoterodineDrug
4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
PlaceboDrug
Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline.Time frame: Baseline and Week 12
Locations
95 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Chandler, Arizona
Pfizer Investigational Site
Peoria, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Rancho Cordova, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Englewood, Colorado
Pfizer Investigational Site
New Britain, Connecticut
Pfizer Investigational Site
Aventura, Florida
Pfizer Investigational Site
Bonita Springs, Florida
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Lake Worth, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Naples, Florida
Pfizer Investigational Site
Pembroke Pines, Florida
Pfizer Investigational Site
St. Petersburg, Florida
Pfizer Investigational Site
Stuart, Florida
Pfizer Investigational Site
Tallahassee, Florida
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Evansville, Indiana
Pfizer Investigational Site
Jeffersonville, Indiana
Pfizer Investigational Site
Newburgh, Indiana
Pfizer Investigational Site
Iowa City, Iowa
Pfizer Investigational Site
Overland Park, Kansas
Pfizer Investigational Site
Overland Park, Kansas
Pfizer Investigational Site
Pratt, Kansas
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Louisville, Kentucky
Pfizer Investigational Site
Madisonville, Kentucky
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Bel Air, Maryland
Pfizer Investigational Site
Milford, Massachusetts
Pfizer Investigational Site
Springfield, Massachusetts
Pfizer Investigational Site
West Yarmouth, Massachusetts
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.